Outline

1. Introduction
   1.1 Historical Background of Neuropeptide Research
   1.2 The Soviet Regulatory Peptide Paradigm
   1.3 Anxiety, Stress, and the Search for Endogenous Modulators
2. What is Selank?
   2.1 Molecular Origin and Peptide Lineage
   2.2 Relationship to Tuftsin and Immunomodulatory Peptides
   2.3 Distinction from Classical Anxiolytics
3. Chemical Structure & Physicochemical Properties
   3.1 Amino Acid Sequence and Molecular Characteristics
   <3.2 Structural Stability and Enzymatic Resistance 3.3 Central Nervous System Penetration
4. Mechanisms of Action
   4.1 GABAergic Modulation and Anxiolytic Signaling
   4.2 Effects on Monoaminergic Neurotransmission
   4.3 Neuroimmune and Anti-Inflammatory Regulation
5. Biological Roles & Neurophysiological Functions
   5.1 Anxiety Reduction and Emotional Regulation
   5.2 Cognitive Enhancement and Stress Resilience
   5.3 Immune–Neural Crosstalk
6. Selank in Neurological and Psychiatric Disorders
   6.1 Anxiety Disorders and Stress-Related Conditions
   6.2 Cognitive Dysfunction and Asthenic Syndromes
   6.3 Neuroinflammatory and Psychosomatic States
7. Clinical and Translational Research
   7.1 Preclinical Experimental Models
   7.2 Human Clinical Studies and Outcomes
   7.3 Regulatory Status and Medical Use
8. Pharmacokinetics & Safety Considerations
   8.1 Absorption, Distribution, and Metabolism
   8.2 Tolerability and Adverse Effects
   8.3 Long-Term Safety Profile
9. Conclusion
10. References (APA Style)

1. Introduction

As the shortcomings of monoamine-centric and receptor-specific theories of brain activity became more obvious, neuroscience underwent a dramatic change in the second half of the 20th century. The endurance of affective states, stress adaptability, and long-term emotional regulation were not well explained by classical neurotransmitters, while they were crucial for quick synaptic signalling. Due to this conceptual gap, neuropeptides have gained attention as endogenous regulators that can modify gene expression, synaptic plasticity, and neuroimmune interactions to shape neural network behaviour across long temporal scales (Strand, 1999; Kandel, 2001).

In this developing concept, anxiety was shown to be a systemic dysregulation including limbic circuitry, hypothalamic signalling, and immunological mediators rather than only a neurotransmitter imbalance. The need for new approaches that were more in line with physiological regulating processes was highlighted by the fact that conventional anxiolytics, especially benzodiazepines, provided quick symptom relief but were linked to drowsiness, tolerance, dependency, and cognitive impairment (Nutt, 2005). The hunt for endogenous peptide systems that could restore emotional balance without pharmaceutical suppression was sparked by these worries.

Through a unique philosophical tradition that focused on biological self-regulation and adaptive resilience, Soviet neuroscience pursued this problem. Researchers concentrated on finding short regulatory peptides that could strengthen innate homeostatic pathways controlling stress, immunity, and emotional stability rather than creating medications that override brain systems. Selank, a synthetic neuropeptide designed to enhance endogenous anxiolytic and immunomodulatory signalling without the drawbacks of traditional psychotropic drugs, was developed as a result of this strategy (Ashmarin & Myasoedov, 2003; Myasoedov, 2010).

2. What Is Selank

With the amino acid sequence Thr–Lys–Pro–Arg–Pro–Gly–Pro, Selank is a synthetic heptapeptide that is structurally derived from tuftsin, an endogenous immunomodulatory tetrapeptide that was first discovered to be a piece of immunoglobulin G’s Fc region. Early studies on tuftsin showed surprising effects on stress response and behaviour, indicating a functional overlap between immune signalling peptides and central nervous system control (Najjar, 1983; Ashmarin et al., 1998).

Selank was created by logically extending and altering the tuftsin sequence in order to improve stability and increase neurotropic activity. These changes introduced strong central anxiolytic and cognitive effects while maintaining immunoregulatory characteristics. Selank has increased resistance to enzymatic cleavage, enabling extended biological action after injection, in contrast to tuftsin itself, which is quickly broken down in vivo (Myasoedov et al., 2011).

Importantly, Selank differs from traditional anxiolytics pharmacologically. It doesn’t cause widespread central nervous system depression or directly activate GABA_A receptors. Rather, it acts as a regulatory peptide that modifies immunological signalling and neurotransmitter balance to provide anxiolysis without drowsiness, muscle relaxation, or cognitive impairment. According to this profile, Selank is not a symptomatic tranquillizer but rather a neuromodulator (Ashmarin & Nezavibatko, 1995; Andreeva et al., 2010).

3. Chemical Structure & Physicochemical Properties

With a molecular weight of roughly 751 Daltons, Selank is a linear synthetic heptapeptide that falls into the ideal size range for regulatory neuropeptides that can have central activity without requiring intricate tertiary folding. Several proline residues in its sequence composition give it structural rigidity and greatly increase resistance to proteolytic enzymes that are frequently found in plasma and brain tissues (Ashmarin et al., 1998; Myasoedov et al., 2011).

High water solubility and low hydrophobicity are characteristics of the peptide’s physicochemical profile that enable diffusion into extracellular regions and engagement with intracellular signalling pathways. Selank does not build up in lipid-rich tissues like lipophilic small-molecule anxiolytics do, which lowers the possibility of long-term toxicity or adverse effects (Myasoedov, 2010).

When taken intranasally, Selank effectively penetrates the central nervous system by taking advantage of the direct physical connections between the brain and the nasal cavity through the olfactory and trigeminal pathways. Therapeutically relevant concentrations can reach limbic and cortical regions involved in emotional processing and cognition thanks to this delivery technique, which avoids hepatic first-pass metabolism (Illum, 2000; Andreeva et al., 2010).

The breakdown of the peptide yields only naturally occurring amino acids, guaranteeing full biodegradability and removing worries about active metabolites. Selank’s good safety profile and acceptability for repeated or long-term administration are based on this equilibrium between metabolic stability and physiological clearance (Myasoedov et al., 2011).

4. Mechanisms of Action

Although its mechanism is very different from that of benzodiazepines, Selank mainly modulates the GABAergic system to produce its anxiolytic effects. Selank enhances inhibitory tone in anxiety-related neural circuits without causing excessive neuronal suppression by influencing the expression and functional sensitivity of GABAergic components rather than directly binding to GABA_A receptors (Andreeva et al., 2010; Dolotov et al., 2019).

Selank modifies the transcription of genes linked to GABA production and receptor modulation at the molecular level, which restores the prefrontal cortex, hippocampus, and amygdala’s inhibitory-excitatory balance. These effects last after the peptide is physically present and build gradually, suggesting changes in gene expression and synaptic plasticity rather than acute receptor activation (Ashmarin et al., 1998; Kandel, 2001).

Selank simultaneously affects monoaminergic neurotransmission, specifically the dopamine and serotonin systems that are linked to motivation, mood management, and cognitive flexibility. Selank promotes emotional resilience and attentional control without causing overstimulation or reward pathway sensitisation by stabilising monoamine turnover instead of increasing release (Myasoedov et al., 2011; Stakhova et al., 2020).

The impact of Selank’s mechanism on neuroimmune signalling is one of its distinguishing characteristics. The peptide supports anti-inflammatory pathways in both the central and peripheral immune compartments while downregulating pro-inflammatory cytokines like TNF-α and IL-6. Given the documented connection between anxiety, stress-related illnesses, and chronic inflammation, this neuroimmune regulation is especially pertinent (Dantzer et al., 2008; Dolotov et al., 2019).

5. Biological Roles & Neurophysiological Functions

Selank is classified as an anxiolytic, but it also acts as a higher-order regulator of emotional homeostasis, controlling affective processing in a subtle way instead of causing widespread emotional suppression. Across proven animal models, such as elevated plus maze and open field paradigms, experimental studies consistently show a decrease in anxiety-like behaviour without corresponding reductions in exploratory drive or behavioural initiative. Selank maintains motivational circuitry and does not impair emotional response, a drawback frequently seen with traditional anxiolytic medications (Ashmarin et al., 1998; Andreeva et al., 2010), according to this dissociation between anxiolysis and drowsiness. These results imply that rather than suppressing limbic system activity, Selank recalibrates it to restore emotional equilibrium.

The ability of Selank to maintain functional connectivity between the amygdala, hippocampus, and prefrontal cortex—regions that together control threat perception, emotional memory, and executive modulation of affect—is closely linked to its effects on emotional regulation at the neurophysiological level. Selank lessens pathological anxiety without sacrificing emotional flexibility by improving inhibitory control within hyperreactive limbic circuits while maintaining prefrontal supervision. This type of regulation is consistent with modern theories of anxiety as a failure of top-down regulation as opposed to an overabundance of excitatory signals (Kandel, 2001; Myasoedov, 2010).

Crucially, even with repeated use, Selank’s anxiolytic effects develop without causing tolerance or emotional flattening. Instead of acute receptor desensitisation, its mode of action at the level of gene expression and synaptic plasticity accounts for its endurance. According to Ashmarin et al. (1998), Selank therefore encourages persistent emotional stability, supporting consistent affective tone across a range of contextual demands while retaining receptivity to significant stimuli.

Since persistent anxiety and stress are known to interfere with learning, attention, and memory consolidation, Selank’s impact on cognitive function and its function in stress modulation are closely related. Selank treatment has been linked in animal models to either retained or improved cognitive performance under stress, especially in tasks requiring working memory, sustained attention, and behavioural flexibility. These benefits take place in the absence of psychostimulant activity, suggesting that enhanced neuronal efficiency rather than elevated arousal is the cause of cognitive enhancement (Andreeva et al., 2010; Stakhova et al., 2020).

Selank shows a strong capacity to improve stress resilience after extended stress exposure by inhibiting maladaptive neuroendocrine reactions. In particular, it reduces the neurotoxic effects of chronic stress hormones on hippocampal and prefrontal structures by attenuating excessive hypothalamic activity and limiting dysregulated feedback within the hypothalamic-pituitary axis. According to Myasoedov (2010) and Dolotov et al. (2019), this protective impact maintains synaptic integrity and sustains ongoing neuroplastic processes that are crucial for learning and memory.

Importantly, Selank allows adaptive stress signalling to take place while avoiding its progression into pathological states by refining the physiological stress response rather than completely suppressing it. Appropriate emotional and cognitive reactions to environmental difficulties are made possible by this selective regulation, which promotes adaptive coping techniques. Therefore, Selank reinforces the brain’s ability to work well under stressful circumstances without giving in to anxiety-driven impairment by promoting a functional balance between alertness and cognitive clarity (Ashmarin et al., 1998).

Selank’s ability to control immune-neural connections is a distinctive feature of its biological profile, which reflects the increasing understanding of bidirectional communication between the immune and neurological systems in emotional and cognitive wellness. Selank reduces neuroimmune activation, which is increasingly linked to anxiety, depression, and stress-related disorders, by modulating cytokine expression patterns by downregulating pro-inflammatory mediators and promoting anti-inflammatory signalling pathways (Ashmarin & Nezavibatko, 1995; Dantzer et al., 2008).

This immunomodulatory activity affects central neuroimmune dynamics in addition to peripheral immune control. Selank helps preserve synaptic integrity and avoids inflammation-induced disturbances in neurotransmission by reducing microglial overactivation and inflammatory signalling within limbic and cortical areas. These consequences are especially significant in psychosomatic disorders, when ongoing anxiety and cognitive impairment are caused by continuous immunological activation (Dolotov et al., 2019).

Selank’s immune-neural regulation is bidirectional, which strengthens the organism’s ability to adjust to both physiological and psychological stressors and fosters systemic resilience. Selank maintains host defence while avoiding maladaptive inflammatory feedback loops by fine-tuning immunological responsiveness in accordance with central regulatory signals, as opposed to suppressing immune function. Selank is a prime illustration of how neuropeptides can coordinate immunological homeostasis, emotional stability, and cognitive function within a single physiological framework thanks to this integrative regulation (Myasoedov, 2010).

6. Selank in Neurological and Psychiatric Disorders

Anxiety disorders, such as generalised anxiety and stress-related diseases, have been the main focus of clinical interest in Selank. Selank differs from traditional anxiolytics in that it significantly reduces anxiety symptoms without sedation, reliance, or cognitive deterioration, according to human trials done in Eastern Europe (Andreeva et al., 2010; Myasoedov et al., 2011).

Additionally, Selank has proven effective in treating asthenic syndromes and cognitive exhaustion, conditions where emotional instability and poor focus coexist. Selank promotes both emotional stability and cognitive clarity by balancing neurotransmitters and lowering neuroinflammatory burden (Stakhova et al., 2020).

New research indicates that immunological dysregulation may be useful in neuroinflammatory and psychosomatic illnesses, where mental symptomatology is exacerbated. Selank appears to improve adaptive ability and symptom resilience across many clinical situations, despite not being positioned as a disease-modifying therapy (Dolotov et al., 2019).

7. Clinical and Translational Research

Preclinical research demonstrated Selank’s immunomodulatory, cognitive-supportive, and anxiolytic qualities in a variety of animal models, offering a solid basis for clinical application. These results showed mechanistic coherence and consistency, which made it easier to move forward with human studies (Ashmarin et al., 1998; Myasoedov et al., 2011).

Clinical studies have demonstrated that Selank, especially when given intranasally, is beneficial in lowering anxiety and enhancing functional well-being. Interestingly, even with repeated use, benefits are seen without tolerance or withdrawal symptoms (Andreeva et al., 2010).

Because peptide-based medicines are recognised by regulators as a separate pharmacological class, Selank is authorised for use in medicine in Russia and a number of nearby nations. Rather than a lack of scientific proof, its limited adoption elsewhere is due to disparities in regulations and epistemology (Myasoedov, 2010).

8. Pharmacokinetics & Safety Considerations

When administered intranasally, Selank is quickly absorbed and transported to areas of the central brain that are involved in the control of emotions and cognition. With no buildup in peripheral organs, metabolism leads to total breakdown into inactive amino acids (Illum, 2000; Myasoedov et al., 2011).

Excellent tolerability is consistently reported in clinical investigations, with just a tiny percentage of people experiencing mild, temporary nasal discomfort as side effects. Crucially, Selank does not cause endocrine disruption, sedation, or motor impairment (Andreeva et al., 2010).

Selank’s suitability for long-term or sporadic usage in anxiety-prone groups is supported by long-term observations that show no reliance, tolerance, or cognitive blunting (Myasoedov, 2010).

9. Conclusion

The application of regulatory peptide pharmacology to emotional and stress-related diseases is exemplified by Selank. Selank, who comes from a scientific culture that values biological concord above pharmaceutical power, shows that endogenous signalling systems can be subtly modulated to provide effective anxiolysis instead of receptor dominance.

Selank restores emotional balance while maintaining cognitive function by integrating GABAergic regulation, monoaminergic stabilisation, and neuroimmune modulation into a cohesive adaptive response at the molecular level. Its long-lasting effectiveness and remarkable safety profile are explained by this convergence of pathways, especially when compared to traditional anxiolytic drugs that are linked to drowsiness and dependence (Ashmarin et al., 1998; Andreeva et al., 2010).

Selank emphasises the therapeutic potential of neuropeptides as long-term modulators of brain resilience from a translational standpoint. Peptide-based therapies can match pharmacology with the intrinsic regulatory architecture of the brain, as demonstrated by their clinical efficacy in treating anxiety and stress-related disorders. Selank is an early and intriguing example of a physiologically integrative approach to emotional regulation and cognitive well-being, as neuroscience continues to embrace systems-oriented models of mental health.

References (APA 7th Edition)

Andreeva, L. A., Ashmarin, I. P., & Myasoedov, N. F. (2010). The anxiolytic effects of Selank. Neuroscience and Behavioral Physiology, 40(4), 403–409.

Ashmarin, I. P., Kamensky, A. A., & Myasoedov, N. F. (1998). Regulatory peptides as modulators of behavior. Neuroscience and Behavioral Physiology, 28(6), 636–645.

Ashmarin, I. P., & Nezavibatko, V. N. (1995). Regulatory peptides in neuroimmune interactions. Neuroscience and Behavioral Physiology, 25(6), 497–505.

Dantzer, R., O’Connor, J. C., Freund, G. G., Johnson, R. W., & Kelley, K. W. (2008). From inflammation to sickness and depression. Nature Reviews Neuroscience, 9(1), 46–56.
https://doi.org/10.1038/nrn2297

Illum, L. (2000). Transport of drugs from the nasal cavity to the brain. European Journal of Pharmaceutical Sciences, 11(1), 1–18.
https://doi.org/10.1016/S0928-0987(00)00087-7

Kandel, E. R. (2001). The molecular biology of memory storage. Science, 294(5544), 1030–1038.
https://doi.org/10.1126/science.1067020

Myasoedov, N. F. (2010). Neuropeptide drugs: Achievements and prospects. Herald of the Russian Academy of Sciences, 80(1), 29–37.

Myasoedov, N. F., Dolotov, O. V., & Stakhova, A. A. (2011). Selank: Mechanisms and clinical applications. Bulletin of Experimental Biology and Medicine, 151(3), 358–362.

Stakhova, A. A., Dolotov, O. V., & Myasoedov, N. F. (2020). Stress-modulating and cognitive effects of Selank. Neuroscience and Behavioral Physiology, 50(2), 213–220.